Механизмы взаимосвязи неалкогольного стеатогепатита и сахарного диабета 2 типа. Возможности таргетной терапии Medline.ru - медико-биологический информационный портал Медлайн.ру

1. World Health Organization: Obesity and overweight fact sheet. http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed 04 Nov 2016.

2. Engin A. The Definition and Prevalence of Obesity and Metabolic Syndrome / A. Engin // Adv Exp Med Biol. - 2017. - N 960. - P. 1-17.

3. Диагностика, лечение, профилактика ожирения и ассоциированных с ним заболеваний (национальные клинические рекомендации). - СПб., - 2017. - 164 с.

4. Younossi Z.M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes / Z.M. Younossi, A.B. Koenig, D. Abdelatif // Hepatology. - 2016. - Vol. 64. - P. 73-84.

5. Nonalcoholic fatty liver disease: Evolving paradigms / A. Lonardo [et al.] // World J Gastroenterol. - 2017. - Vol. 23, N 36. - P. 6571-6592.

6. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases / L.A. Adams [et al.] // Gut. - 2017. - Vol. 66. - P. 1138-53.

7. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases / N. Chalasani [at al.] // J. Hepatology. - 2018. - Vol. 67, N 1. - P. 328-357.

8. Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001-2010: report of the committee on causes of death in diabetes mellitus / J. Nakamura [at al.] // J Diabetes Invest. - 2017. - N 8. - P. 397-410.

9. Клинические рекомендации EASL-EASD-EASO по диагностике и лечению неалкогольной жировой болезни печени. Journal of Hepatology. - 2016. - vol. 64. P. 1388-1402.

10. Caligiuri A. Molecular Pathogenesis of NASH / A. Caligiuri, A. Gentilini, F. Marra // Int J Mol Sci. - 2016. - Vol. 17, N 9. - P. 1575.

11. Potential Nexus of Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Insulin Resistance Between Hepatic and Peripheral Tissues / W. Mu [at al.] // Front Pharmacol. -2019. - Vol. 14, N 9. - P. 1566.

12. The interaction of hepatic lipid and glucose metabolism in liver diseases / L. P. Bechmann, R. A. [at al.] // Journal of Hepatology. - 2012. - Vol. 56, N 4. - P. 952-964.

13. Czech M.P. Insulin action and resistance in obesity and type 2 diabetes / M.P. Czech // Nat. Med. - 2017. - Vol. 23. - P. 804-814.

14. Samuel V.T. Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases / V.T. Samuel, G.I. Shulman // Cell Metab. - 2018. - N 27. - P. 22-41.

15. The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans / S. Ballestri [at al.] // Adv Ther. - 2016. - N 33. - P. 291-319.

16. Johnson A.M. The origins and drivers of insulin resistance / A.M. Johnson, J. M. Olefsky // Cell. - 2013. - N 152. - P. 673-684.

17. Haeusler R. A. Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors / R.A. Haeusler // Nat. Commun. - 2014. - N 5. - P. 5190.

18. Catrysse L. Inflammation and the metabolic syndrome: the tissue-specific functions of NF-kappaB / L. Catrysse, van Loo G. // Trends Cell Biol. - 2017. - N 27. - P. 417-429.

19. Haas J.T. Pathophysiology and mechanisms of nonalcoholic fatty liver disease / J.T. Haas, S. Francque, B. Staels // Annu. Rev. Physiol. - 2016. - N 78. - P. 181-205.

20. Lallukka S. Non-alcoholic fatty liver disease and risk of type 2 diabetes / S. Lallukka,, H. Yki-Jarvinen // Best Pract. Res. Clin. Endocrinol. Metab. - 2016. - N 30. P. 385-395.

21. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome / A. Lonardo [at al.] // Dig Liver Dis. - 2015. - ? 47. N 181-190.

22. Bariatric surgery and non-alcoholic fatty liver disease: a systematic review of liver biochemistry and histology / G. Bower [et al.] // Obes Surg. - 2015. - Vol. 25, N 12. - P. 2280-2289.

23. Independent Association Between Improvement of Nonalcoholic Fatty Liver Disease and Reduced Incidence of Type 2 Diabetes / H. Yamazaki [et al.] // H. Diabetes Care. - 2015. - N 38. - P. 1673-1679.

24. Transient remission of nonalcoholic fatty liver disease decreases the risk of incident type 2 diabetes mellitus in Japanese men / T. Fukuda T [et al.] // Eur J Gastroenterol Hepatol. - 2016. - N 28. - P. 1443-1449.

25. Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study / S.K. Park [et al.] // Hepatology. - 2013. - N 57. P. 1378-1383.

26. Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH / K. Shiba [et al.] // Sci Rep. - 2018. - N 8. - P. 2362.

27. The Effect of Bariatric Surgery on the Spectrum of Fatty Liver Disease / J. Can [et al.] // J Gastroenterol Hepatol. - 2016. - PMCID: PMC5061986.

28. Karpen S.J. Do therapeutic bile acids hit the sweet spot of glucose metabolism in NAFLD? / S.J. Karpen // Gastroenterology. - 2013. - N 145. - P. 508-10.

29. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease / G. Porez et al. // J Lipid Res. - 2012. - N 53. - P. 1723-37.

30. Discovery of tropifexor (ljn452), a highlypotent non-bile acid FXR agonist for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (NASH) / D.C. Tully [et al.] // J Med Chem. - 2017. N 60. - P. 9960-9973.

31. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease / S. Mudaliar [et al.] // Gastroenterology. - 2013. - N 145. - P. 574-582.

32. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis / A.J. Sanyal [et al.] // N Engl J Med. - 2010. -N 362. - P. 1675-1685.

33. Molecular mechanism of PPAR alpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease / M. Pawlak,, P. Lefebvre, B. Staels // J. Hepatol. - 2015. - N 62. - P. 720-733.

34. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening / V. Ratziu // Gastroenterology. - 2015. - N150. - P. 1147-1159.

35. Dual PPARa/g agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models / M.R. Jain [et al.] // Liver Int. - 2018. - N 38. - P. 1084-1094.

36. Drucker D.J. Mechanisms of action and therapeutic application of glucagonlike peptide-1 / D.J. Drucker // Cell Metab. - 2018. - N 27. - P. 740-756.

37. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice / J.L. Trevaskis [et al.] // Am J Physiol Gastrointest Liver Physiol. - 2012. - N 302. - P. G762-G772.

38. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials / T. Vilsboll [et al.] // BMJ. - 2012. - N 344:d7771.

39. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study / M.J. Armstrong [et al.] // Lancet. - 2015. - [ePub Nov 19].

40. Pharmacological inhibition to examine the role of DGAT1 in dietary lipid absorption in rodents and humans / B.S. Maciejewski [et al.] // Am. J. Physiol. Gastrointest. Liver Physiol. - 2013. - N 304ю -P. G958-G969.

41. Coenzyme A: diacylglycerol acyltransferase 1 inhibitor ameliorates obesity, liver steatosis, and lipid metabolism abnormality in KKAy mice fed high-fat or high-carbohydrate diets / T. Yamamoto [et al.] // Eur J Pharmacol. - 2010. - N 640. - P. 243-249.

42. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis / K. Yamaguchi [et al.] // Hepatology. - 2007. -N 45. - P. 1366-1374.

43. Yang M. MOGAT2: a new therapeutic target for metabolic syndrome / M. Yang, J.T. Nickels // Diseases. - 2015. - N 3. - P. 176-192.

44. (2015). JTP-103237, a novel monoacylglycerol acyltransferase inhibitor, modulates fat absorption and prevents diet-induced obesity / C. Okuma [et al.] // Eur. J. Pharmacol. - 2015. - N 758. - P. 72-81.

45. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats / Y. Hayashizaki-Someya [et al] // Eur J Pharmacol. - 2015. - N 754. - P. 19-24.

46. Finck B.N. Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis / B.N. Finck // Diabetes. - 2018. - Vol. 67, N 12ю - P. 2485-2493.

47. Loss of mitochondrial pyruvate carrier 2 in the liver leads to defects in gluconeogenesis and compensation via pyruvatealanine cycling / K.S. McCommis [et al.] // Cell Metab. - 2015. - N 22. - P. 682-694.

48. Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis / K.S. McCommis [et al.] // Hepatology. - 2017. - N 65. - P. 1543-1556.